181 related articles for article (PubMed ID: 36859467)
1. Maximum dose, safety, tolerability and ketonemia after triheptanoin in glucose transporter type 1 deficiency (G1D).
Málaga I; Avila A; Primeaux S; Kallem RR; Roe CR; Putnam WC; Park JY; Shinnar S; Ahn C; Pascual JM
Sci Rep; 2023 Mar; 13(1):3465. PubMed ID: 36859467
[TBL] [Abstract][Full Text] [Related]
2. Combination of triheptanoin with the ketogenic diet in Glucose transporter type 1 deficiency (G1D).
Avila A; Málaga I; Sirsi D; Kayani S; Primeaux S; Kathote GA; Jakkamsetti V; Kallem RR; Putnam WC; Park JY; Shinnar S; Pascual JM
Sci Rep; 2023 Jun; 13(1):8951. PubMed ID: 37268656
[TBL] [Abstract][Full Text] [Related]
3. Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement.
Pascual JM; Liu P; Mao D; Kelly DI; Hernandez A; Sheng M; Good LB; Ma Q; Marin-Valencia I; Zhang X; Park JY; Hynan LS; Stavinoha P; Roe CR; Lu H
JAMA Neurol; 2014 Oct; 71(10):1255-65. PubMed ID: 25110966
[TBL] [Abstract][Full Text] [Related]
4. Glut1 deficiency (G1D): epilepsy and metabolic dysfunction in a mouse model of the most common human phenotype.
Marin-Valencia I; Good LB; Ma Q; Duarte J; Bottiglieri T; Sinton CM; Heilig CW; Pascual JM
Neurobiol Dis; 2012 Oct; 48(1):92-101. PubMed ID: 22683290
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind trial of triheptanoin for drug-resistant epilepsy in glucose transporter 1 deficiency syndrome.
Striano P; Auvin S; Collins A; Horvath R; Scheffer IE; Tzadok M; Miller I; Kay Koenig M; Lacy A; Davis R; Garcia-Cazorla A; Saneto RP; Brandabur M; Blair S; Koutsoukos T; De Vivo D
Epilepsia; 2022 Jul; 63(7):1748-1760. PubMed ID: 35441706
[TBL] [Abstract][Full Text] [Related]
6. Triheptanoin--a medium chain triglyceride with odd chain fatty acids: a new anaplerotic anticonvulsant treatment?
Borges K; Sonnewald U
Epilepsy Res; 2012 Jul; 100(3):239-44. PubMed ID: 21855298
[TBL] [Abstract][Full Text] [Related]
7. Glucose Transporter Type I Deficiency (G1D) at 25 (1990-2015): Presumptions, Facts, and the Lives of Persons With This Rare Disease.
Pascual JM; Ronen GM
Pediatr Neurol; 2015 Nov; 53(5):379-93. PubMed ID: 26341673
[TBL] [Abstract][Full Text] [Related]
8. Triheptanoin for the treatment of brain energy deficit: A 14-year experience.
Mochel F
J Neurosci Res; 2017 Nov; 95(11):2236-2243. PubMed ID: 28688166
[TBL] [Abstract][Full Text] [Related]
9. Dietary management and major clinical events in patients with long-chain fatty acid oxidation disorders enrolled in a phase 2 triheptanoin study.
Vockley J; Longo N; Madden M; Dwyer L; Mu Y; Chen CY; Cataldo J
Clin Nutr ESPEN; 2021 Feb; 41():293-298. PubMed ID: 33487279
[TBL] [Abstract][Full Text] [Related]
10. Heptanoate as a neural fuel: energetic and neurotransmitter precursors in normal and glucose transporter I-deficient (G1D) brain.
Marin-Valencia I; Good LB; Ma Q; Malloy CR; Pascual JM
J Cereb Blood Flow Metab; 2013 Feb; 33(2):175-82. PubMed ID: 23072752
[TBL] [Abstract][Full Text] [Related]
11. Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment--A retrospective chart review.
Vockley J; Marsden D; McCracken E; DeWard S; Barone A; Hsu K; Kakkis E
Mol Genet Metab; 2015; 116(1-2):53-60. PubMed ID: 26116311
[TBL] [Abstract][Full Text] [Related]
12. A concise study of acetazolamide in glucose transporter type 1 deficiency (G1D) epilepsy.
Málaga I; Avila A; Primeaux S; Park JY; Pascual JM
Epilepsia; 2023 Sep; 64(9):e184-e189. PubMed ID: 37335529
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of triheptanoin in metabolic and neurodegenerative diseases.
Wehbe Z; Tucci S
J Inherit Metab Dis; 2020 May; 43(3):385-391. PubMed ID: 31778232
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of add-on oral triheptanoin treatment for children with medically refractory epilepsy.
Calvert S; Barwick K; Par M; Ni Tan K; Borges K
Eur J Paediatr Neurol; 2018 Nov; 22(6):1074-1080. PubMed ID: 30126760
[TBL] [Abstract][Full Text] [Related]
15. Clinical Aspects of Glucose Transporter Type 1 Deficiency: Information From a Global Registry.
Hao J; Kelly DI; Su J; Pascual JM
JAMA Neurol; 2017 Jun; 74(6):727-732. PubMed ID: 28437535
[TBL] [Abstract][Full Text] [Related]
16. Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats.
Kinman RP; Kasumov T; Jobbins KA; Thomas KR; Adams JE; Brunengraber LN; Kutz G; Brewer WU; Roe CR; Brunengraber H
Am J Physiol Endocrinol Metab; 2006 Oct; 291(4):E860-6. PubMed ID: 16705058
[TBL] [Abstract][Full Text] [Related]
17. Triheptanoin: long-term effects in the very long-chain acyl-CoA dehydrogenase-deficient mouse.
Tucci S; Floegel U; Beermann F; Behringer S; Spiekerkoetter U
J Lipid Res; 2017 Jan; 58(1):196-207. PubMed ID: 27884962
[TBL] [Abstract][Full Text] [Related]
18. Reduced severity of ischemic stroke and improvement of mitochondrial function after dietary treatment with the anaplerotic substance triheptanoin.
Schwarzkopf TM; Koch K; Klein J
Neuroscience; 2015 Aug; 300():201-9. PubMed ID: 25982559
[TBL] [Abstract][Full Text] [Related]
19. UX007 for the treatment of long chain-fatty acid oxidation disorders: Safety and efficacy in children and adults following 24weeks of treatment.
Vockley J; Burton B; Berry GT; Longo N; Phillips J; Sanchez-Valle A; Tanpaiboon P; Grunewald S; Murphy E; Humphrey R; Mayhew J; Bowden A; Zhang L; Cataldo J; Marsden DL; Kakkis E
Mol Genet Metab; 2017 Apr; 120(4):370-377. PubMed ID: 28189603
[TBL] [Abstract][Full Text] [Related]
20. The Pharmacokinetics of Triheptanoin and Its Metabolites in Healthy Subjects and Patients With Long-Chain Fatty Acid Oxidation Disorders.
Lee SK; Gupta M; Shi J; McKeever K
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1325-1334. PubMed ID: 33789001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
